Jamie E. Chaft, Masahiro Tsuboi, Walter Weder. "Reply to: “NeoADAURA: Can We Afford to Overlook Objective Response Rates?” and “Is Major Pathologic Response the Best Surrogate End Point for Neoadjuvant Trials?”." Journal of Clinical Oncology, 2026. doi:10.1200/jco-25-02551